{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:23Z","timestamp":1791223763393,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T00:00:00Z","timestamp":1424131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["#310030-143584"],"award-info":[{"award-number":["#310030-143584"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swiss Cancer League","award":["KLS-2520-02-2010"],"award-info":[{"award-number":["KLS-2520-02-2010"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early relapse is common in patients with mantle cell lymphoma (MCL) highlighting the unmet need for further improvement of therapeutic options for these patients. CD20 inhibition combined with induction chemotherapy as well as consolidation with high\u2010dose chemotherapy (HDCT) is increasingly considered cornerstones within current therapy algorithms of MCL whereas the role of radioimmunotherapy is unclear. This retrospective single center study compared 46 consecutive MCL patients receiving HDCT in first or second remission. Thirty\u2010five patients had rituximab and BEAM (R\u2010BEAM), and 11 patients received ibritumomab tiuxetan (Zevalin\u00ae), an Yttrium\u201090 labeled CD20 targeting antibody, prior to BEAM (Z\u2010BEAM) followed by autologous stem cell transplantation (ASCT). We observed that the 5\u2010year overall survival (OS) in the R\u2010BEAM and Z\u2010BEAM groups was 55% and 71% (<jats:italic>p<\/jats:italic>\u2009=\u20090.288), and the 4\u2010year progression free survival (PFS) was 32% and 41%, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.300). There were no treatment related deaths in both groups, and we observed no differences in toxicities, infection rates or engraftment. Our data suggest that the Z\u2010BEAM conditioning regimen followed by ASCT is well tolerated, but was not associated with significantly improved survival compared to R\u2010BEAM. Copyright \u00a9 2015 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2197","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T09:16:24Z","timestamp":1424164584000},"page":"133-139","source":"Crossref","is-referenced-by-count":14,"title":["Zevalin and BEAM (Z\u2010BEAM) versus rituximab and BEAM (R\u2010BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma"],"prefix":"10.1002","volume":"34","author":[{"given":"Martin D.","family":"Berger","sequence":"first","affiliation":[{"name":"Department of Medical Oncology University Hospital  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Branger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Klaeser","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine University Hospital  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz Mansouri","family":"Taleghani","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[{"name":"Institute of Pathology University of Berne  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice U.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Clinical Research University of Berne  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/asheducation-2009.1.542","article-title":"European MCL Network. Current treatment standards and emerging strategies in mantle cell lymphoma","volume":"24","author":"Dreyling M","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23176"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-179739"},{"key":"e_1_2_4_6_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/blood.V116.21.110.110","article-title":"Alternating Courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA\u2010C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)","volume":"116","author":"Hermine O","year":"2010","journal-title":"Blood"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-S2-41"},{"key":"e_1_2_4_9_1","first-page":"62","article-title":"Principles of radioimmunotherapy for hematologists and oncologists","volume":"27","author":"Press OW","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_4_10_1","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y\u2010ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non\u2010Hodgkin's lymphoma: combined data from 4 clinical trials","volume":"44","author":"Wiseman GA","year":"2003","journal-title":"J Nucl Med"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.160"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22617"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.007"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.108308"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.07.024"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27418"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9283-z"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9248"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1310"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291702"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2934"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.01.043"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.434"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541953"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04140.x"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8545"},{"key":"e_1_2_4_30_1","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1182\/blood.V106.11.4786.4786","article-title":"Efficacy and safety of a single\u2010course of yttrium\u201090 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory mantle cell lymphoma (MCL) after\/not appropriate for autologous stem cell transplantation (ASCT)\u2014a phase II trial of the European MCL network","volume":"106","author":"Weigert O","year":"2005","journal-title":"Blood"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2197","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T06:47:50Z","timestamp":1696488470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,17]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/hon.2197"],"URL":"https:\/\/doi.org\/10.1002\/hon.2197","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,17]]}}}